Samarium-153-EDTMP in Bone Metastases of Hormone Refractory Prostate Carcinoma: A Phase I/II Trial

Samarium-153-ethylenediaminetetramethylene phosphoric acid (EDTMP), a bone-seeking radiopharmaceutical, was given to prostate cancer patients in a dose escalation protocol for pain palliation to determine the maximally tolerated dose. Fifty-two patients with hormone refractory prostate cancer with b...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of nuclear medicine (1978) Vol. 34; no. 11; p. 1839
Main Authors Collins, Carolyn, Eary, Janet F, Donaldson, Gary, Vernon, Cheryl, Bush, Nigel E, Petersdorf, Stephen, Livingston, Robert B, Gordon, Edwin E, Chapman, C. Richard, Appelbaum, Frederick R
Format Journal Article
LanguageEnglish
Published United States Soc Nuclear Med 01.11.1993
Subjects
Aged
Aged, 80 and over
Bone Neoplasms - diagnostic imaging
Bone Neoplasms - radiotherapy
Bone Neoplasms - secondary
Hormones - therapeutic use
Humans
Male
Middle Aged
Organometallic Compounds - adverse effects
Organometallic Compounds - therapeutic use
Organophosphorus Compounds - adverse effects
Organophosphorus Compounds - therapeutic use
Pain Measurement
Prostatic Neoplasms - drug therapy
Prostatic Neoplasms - pathology
Radioisotopes - adverse effects
Radioisotopes - therapeutic use
Radionuclide Imaging
Radiotherapy Dosage
Samarium - adverse effects
Samarium - therapeutic use
Online AccessGet full text

Cover

More Information
Summary:Samarium-153-ethylenediaminetetramethylene phosphoric acid (EDTMP), a bone-seeking radiopharmaceutical, was given to prostate cancer patients in a dose escalation protocol for pain palliation to determine the maximally tolerated dose. Fifty-two patients with hormone refractory prostate cancer with bony metastases were treated with doses beginning at 0.5 mCi/kg (18.5 MBq/kg), escalating in 0.5-mCi (18.5 MBq) increments to 3.0 mCi/kg (111 MBq/kg). Pain response after treatment was assessed as well as hematologic and serum chemistry parameters. Pain palliation with a mean duration of 2.6 mo was present in 74% of the patients. Toxicity was exclusively hematologic at the highest dose levels. No infectious or bleeding complications occurred, with 45 of the 52 (86%) patients demonstrating complete hematologic recovery. Patients receiving higher doses had significantly greater reductions in serum prostate specific antigen and serum prostatic acid phosphatase levels. The patients receiving greater doses also showed a trend toward improved survival.
ISSN:0161-5505
1535-5667